Pirarubicin is a new anthracycline anticancer agent structurally related to doxorubicin. In
acute leukemia, non-Hodgkin’s lymphoma, breast and ovariail carcinoma, pirarubicin is
reportedly superior to doxorubicin and better tolerated. Its major side-effect appears to be
myelosuppression, mainly in the form of leucopenia, which is potentially dose-limiting.
Structural analog of Doxorubicin. Antineoplastic.
ChEBI: (7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-6-methyl-5-[[(2R)-2-oxanyl]oxy]-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione is an anthracycline.
Pinorubicin; Therarubucin
